Celldex Therapeutics (CLDX) Payables (2016 - 2025)
Historic Payables for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $4.3 million.
- Celldex Therapeutics' Payables rose 28303.41% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 28303.41%. This contributed to the annual value of $3.3 million for FY2024, which is 655.41% down from last year.
- Latest data reveals that Celldex Therapeutics reported Payables of $4.3 million as of Q3 2025, which was up 28303.41% from $2.1 million recorded in Q2 2025.
- In the past 5 years, Celldex Therapeutics' Payables registered a high of $4.3 million during Q3 2025, and its lowest value of $685000.0 during Q2 2021.
- Its 5-year average for Payables is $2.3 million, with a median of $2.3 million in 2022.
- Data for Celldex Therapeutics' Payables shows a peak YoY increase of 33155.51% (in 2024) and a maximum YoY decrease of 6893.47% (in 2024) over the last 5 years.
- Quarter analysis of 5 years shows Celldex Therapeutics' Payables stood at $1.2 million in 2021, then skyrocketed by 171.99% to $3.3 million in 2022, then increased by 4.61% to $3.5 million in 2023, then fell by 6.55% to $3.3 million in 2024, then skyrocketed by 30.69% to $4.3 million in 2025.
- Its last three reported values are $4.3 million in Q3 2025, $2.1 million for Q2 2025, and $3.4 million during Q1 2025.